Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

Table 4

Multivariate analysis PFS.

Parameters	HR	95% confidence interval		value
		Lower boundary	Upper boundary
Ki67 level	0.731	0.441	1.212	0.224
Allred score	2.073	1.152	3.732	0.015
PR-status	1.230	0.641	2.362	0.53
Site of metastasis	1.392	0.472	4.105	0.548
Site of metastasis (single)	0.275	0.109	0.692	0.006